Patients & Caregivers
Contact Us
Français
Home
Overview
Major Accomplishments
Working at Merck
Search Jobs, Submit Resume, Log on
Career Choices
Students and recent Grads
Careers Questions
Partners
Company Overview
Community Relations
Frequently Asked Questions
VIOXX® Information Center
Terms and Conditions of Sales
Corporate News
Executive Speeches
Product News
Research & Development News
Media Contact
Newsroom
Corporate News
Photos
Executive Speeches
Product News
CANCIDAS
®
COSOPT
®
COZAAR
®
CRIXIVAN
®
EMEND
®
FOSAMAX
®
FOSAVANCE
®
GARDASIL
®
INTRON A
®
INVANZ
®
ISENTRESS
®
JANUMET
TM
JANUVIA
®
MAXALT
®
PEGETRON
®
PROPECIA
®
PROSCAR
®
ROTATEQ
®
SINEMET
®
SINGULAIR
®
VARIVAX
®
III
VASOTEC
®
VICTRELIS
TM
VIOXX
®
ZOCOR
®
ZOLINZA
®
ZOSTAVAX
TM
EZETROL
®
Research & Development News
Media Contact
Research & Development News
March 30, 2011
The New England Journal of Medicine Publishes Pivotal Studies Showing Potential of New Investigational Treatment for Chronic Infection with Hepatitis C Virus Genotype 1
November 18, 2010
In Phase III Study Merck's Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with coronary heart disease (CHD)
October 5, 2010
Canadians With Asthma Consider Their Disease 'Well Controlled' Despite Severe Episodes According To A New Survey
October 5, 2010
Backgrounder - Asthma In Canada And Survey
August 11, 2010
Merck Reports that Two Pivotal Phase III Registration Studies for Boceprevir Have Been Completed and Meet the Primary Endpoints
Printer friendly
This site is for residents of Canada. / This site was updated on October 26, 2011.